Efficacy of desonide 0.05% cream and lotion in steroid-responsive dermatoses in Indian patients: A post-marketing surveillance study

Indian Journal of Dermatology, Venereology and Leprology

Volumn 70, Issue 5, 2004, Pages 288-291

  Bhankharia, Dimple A ^a   Sanjana, Percy H ^b  

^a Galderma India Pvt Ltd ^*

^b Galderma India Pvt Ltd   (India)

Author keywords

Desonide; Efficacy; Indian patients; Infants; Safety; Steroid responsive dermatoses

Indexed keywords

CORTICOSTEROID; DESONIDE; STEROID;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; CREAM; DERMATITIS; DISEASE SEVERITY; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; HUMAN; INDIA; INFANT; LOTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; PHASE 4 CLINICAL TRIAL; POSTMARKETING SURVEILLANCE; SKIN DISEASE;

EID: 33646532257     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Prawer SE, Katz HI, Herndon JH, Baker MD, Cheney T. A Controlled, bilateral, comparative evaluation of 0.05% desonide lotion and desonide cream in eczematous dermatitis. Curr Ther Res 1993;53:607-13.
2. Chren MM, Bickers DR. Dermatological Pharmacology. In: Gilman AG, Rall TW, Nies AS, Taylor P, editors. Goodman and Gilman's -The pharmacological basis of therapeutics. New York: Pergamon Press; 1990. p. 1572-92.
3. Bangham AD, Standish MM, Weismann G. The action of steroids and streptolysin S on the permeability of phospholipid structures to cations. J Mol Biol 1963;13:253-9.
4. Barsky S. Clinical comparison of desonide cream with fluocinonide cream in steroid responsive dermatologic disorders. Cutis 1976;18:826-30.
5. Bluefarb SM. Clinical comparison of desonide cream with betamethasone valerate cream. A double blind randomized study. Int J Dermatol 1972;11:73-6.
6. Henrijean A, Lapiere CM. Clinical evaluation of desonide cream. Curr Ther Res 1983;33:775-81.
7. Donsky HJ. A comparative double-blind randomized clinical study of a new, non-fluorinated topical corticosteroid. Cutis 1972;46-8.
8. Gentry WC Jr, Rosenberg EW, Goltz RW. A clinical evaluation of 0.05% desonide cream - a new nonfluorinated topical corticosteroid. Arch Dermatol 1973;107:870-1.
9. Reque PG. The treatment of common dermatoses with topically applied 0.05% desonide cream. J Med Assoc State Ala 1972;42:25-7.
10. Freeman S, Howard A, Foley P, Rosen R, Wood G, See J, et al. Efficacy, cutaneous tolerance and cosmetic acceptability of desonide 0.05% lotion (Desowen) versus vehicle in the short - term treatment of facial atopic and seborrheic dermatitis. Australas J Dermatol 2002;45:186-9.
11. Cornell RC, Baker MD. Dermal safety comparison of 0.05% desonide cream and 1% hydrocortisone cream. Curr Ther Res 1993;53:356-9.
12. Smith EB, Gregory JF, Bartruff JK. Desonide: A potent non-fluorinated topical steroid, vasoconstriction assay and clinical trial. South Med J 1973;66:325-9.
13. Leyden JJ, Thew M, Kligman AM. Steroid rosacea. Arch Dermatol 1974;110:619-22.
14. Sneddon I. Perioral dermatitis. Br J Dermatol 1972;82:430.
15. Sneddon I. Adverse effects of topical fluorinated corticosteroids in rosacea. Br Med J 1969;1:671-3.
16. Ellison JA, Patel L, Ray DW, David TJ, Clayton PE. Hypothalamic pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics 2000;105:794-9.
17. Jorizzo J, Levy M, Lucky A, Shavin J, Goldberg G, Dunlap F, et al. Multicenter trial for long term safety and efficacy comparison of 0.05% desonide and 1% hydrocortisone ointments in the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 1995;33:74-7.